Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Obstructive Lung Disease
•
Asthma
What is your preferred rescue inhaler for patients with asthma?
Do you favor albuterol PRN, albuterol/budesonide PRN, or SMART therapy with ICS/formoterol?
Answer from: at Community Practice
The problem with using ICS/formoterol is that the patient will run out of doses before the end of the month if they take it on a BID basis.
Sign in or Register to read more
Answer from: at Academic Institution
SMART with ICS/formoterol. I tend to think all asthma patients should be on SMART therapy (ICS/formoterol). Just don't really see the reason to not treat that way.
Sign in or Register to read more
26869
27010
Related Questions
What is the rationale/evidence to support doing 4 puffs of albuterol vs. 2 puffs for a reversibility study?
Have you observed adverse mental health side effects in patients who start montelukast?
What is your preferred biologic in children and adolescents with T2 high asthma?
What is your approach to de-escalation of asthma inhaler therapy in the setting of negative bronchoprovocation testing when patients are averse to deprescribing?
Do you feel high dose Symbicort or Dulera is appropriate to use for SMART despite these doses not being studied in clinical trials?
Should in-office oscillometry for lung function measurements be utilized in pediatric patients who are unable to reliably perform spirometry?
Do you prescribe lower dose ICS for asthma to mitigate the risk of pneumonia in patients with a history of respiratory infections or compromised immune systems?
Do you routinely consider evaluation for EDAC in patients with asthma or COPD on maximal inhaler therapy who have refractory symptoms?
What role might depemokimab play in the stepwise approach to asthma management, especially for patients who have previously failed other biologic therapies?
How do you mitigate the risk of inadverdent under or over diagnosis of COPD in certain populations with transition to race-neutral spirometry reference equations?